Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • FTSE 100

    8,225.03
    +52.88 (+0.65%)
     

  • Bitcoin USD

    61,565.54
    +3,122.00 (+5.34%)
     

  • CMC Crypto 200

    1,326.42
    +49.44 (+3.87%)
     

  • S&P 500

    5,112.98
    +48.78 (+0.96%)
     

  • Dow

    38,623.66
    +398.00 (+1.04%)
     

  • Nasdaq

    16,109.14
    +268.18 (+1.69%)
     

  • Gold

    2,302.40
    -7.20 (-0.31%)
     

  • Crude Oil

    78.57
    -0.38 (-0.48%)
     

  • 10-Yr Bond

    4.5040
    -0.0670 (-1.47%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?

Vandana Singh
·2-min read

On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024.

VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options.

  • Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule:

  • The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT) in any patients, and no patients have discontinued VIP236 due to an adverse event.

  • No severe or life-threatening diarrhea has been observed, validating the purposeful design of VIP236’s optimized camptothecin payload.

  • Seven patients have achieved objective stable disease, including tumor reduction. Four patients remain on the study, with the longest-treated patient for 168 days.

ADVERTISEMENT

VNC-943-101 is a Phase 1 dose-escalation study with monotherapy VIP943 for CD123+ acute myeloid leukemia, B-cell acute lymphocytic leukemia, or myelodysplastic syndromes.

  • VIP943 is administered once per week.

  • No DLTs occurred in Cohort 1 and 2. Four patients have been enrolled in Cohort 3 (0.7 mg/kg) and are undergoing DLT assessment.

  • VIP943 PK data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically.

Vincerx will present additional Phase 1 data for VIP236 and VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.

Vincerx also reported preclinical experiments applying the next-generation effector chemistry of its VersAptx platform to the antibodies of approved antibody-drug conjugates (ADCs), Trodelvy and Enhertu, demonstrating the potential to improve tumor toxicity of ADCs by orders of magnitude.

  • In in vitro tumor models, Vincerx’s sacituzumab-legumain-KSPi ADC had a 20-fold improvement in tumor toxicity compared with Trodelvy (sacituzumab-govitecan).

  • The company’s trastuzumab-legumain-KSPi ADC demonstrated an 8-fold increase in tumor toxicity compared with Enhertu (fam-trastuzumab-deruxtecan).

Price Action: VINC shares are down 73.30% at $1.27 on the last check Tuesday.

Photo via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.